[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Wang et al., 2016 - Google Patents

Solid-state characterization of 17β-estradiol co-crystals presenting improved dissolution and bioavailability

Wang et al., 2016

Document ID
9607693085509884682
Author
Wang J
Wang X
Yang Y
Chen X
Mei X
Publication year
Publication venue
CrystEngComm

External Links

Snippet

17β-estradiol (E2) is a steroid hormone with low oral bioavailability due to its low aqueous solubility (0.2–5 μg mL− 1). To improve its solubility and thus bioavailability, two co-crystals of E2 with isonicotinamide (INA)(1) and piperazine (PIP)(2) were successfully designed and …
Continue reading at pubs.rsc.org (other versions)

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes

Similar Documents

Publication Publication Date Title
Wang et al. Solid-state characterization of 17β-estradiol co-crystals presenting improved dissolution and bioavailability
US20120309968A1 (en) Polymorphs of dasatinib, preparation methods and pharmaceutical compositions thereof
Zhou et al. Crystal structures, dissolution and pharmacokinetic study on a novel phosphodiesterase-4 inhibitor chlorbipram cocrystals
AU2011307608B2 (en) Crystalline naloxol-PEG conjugate
Lin et al. Preparation, characterization, and evaluation of dipfluzine–benzoic acid co-crystals with improved physicochemical properties
Tanaka et al. Application of spray freeze drying to theophylline-oxalic acid cocrystal engineering for inhaled dry powder technology
US20150344435A1 (en) Process for preparating ivabradine hydrochloride form iv and methods of treatment of disease using ivabradine hydrochloride form iv
AU2014351028B2 (en) Solid forms of Ivacaftor and processes for the preparation thereof
Zhu et al. Stable cocrystals and salts of the antineoplastic drug apatinib with improved solubility in aqueous solution
AU2018303293B2 (en) Amorphous form of vilanterol trifenatate and processes for the preparation thereof
CN103360331B (en) Novel lamotrigine pharmaceutical co-crystal and preparation method thereof
WO2018010622A1 (en) Crystalline form of chemical compound, and preparation method, composition, and application thereof
Cai et al. Process control and in vitro/in vivo evaluation of aripiprazole sustained-release microcrystals for intramuscular injection
CN103936808A (en) Isonicotinamide eutectic crystal of 17beta estradiol, and preparation method and application thereof
CN112778290B (en) A kind of addition salt of S1P1 receptor agonist and its crystal form and pharmaceutical composition
Chen et al. Pharmaceutical cocrystals of nomegestrol acetate with superior dissolution
EP2897955B1 (en) New tiotropium bromide crystalline form
EP2681212A1 (en) Crystalline compound comprising tiotropium bromide
CN110078679A (en) A kind of lamotrigine pharmaceutical co-crystal and its preparation method and application
MX2009007785A (en) Inclusion complex of raloxifene hydrochloride and beta-cyclodextrin.
US20180291049A1 (en) Crystalline Forms of Fosnetupitant
JP6594325B2 (en) Crystal forms of tiotropium bromide and lactose
Zhang et al. Dosable solvates of ivacaftor with high boiling point liquids
JP2018531249A6 (en) Crystalline form of Phosnetupitant
WO2023187086A1 (en) Amorphous solid form of amcenestrant